Drawing from research on sepsis and complement biology, they developed the monoclonal antibody vilobelimab to block overactive inflammatory responses in patients with severe inflammatory diseases ...

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.

In a new report posted online in the American Journal of Respiratory and Critical Care Medicine, a global consensus conference of 32 critical care experts with broad international representation and ...

(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced on Wednesday that the European Commission or EC has granted marketing ...

DUBLIN--(BUSINESS WIRE)--The "Global Acute Respiratory Distress Syndrome Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by End-User, Mode of Administration, Treatment Mode, ...

During a session at the American Thoracic Society (ATS) 2024 International Conference, experts presented the most impactful data from the last year on acute respiratory distress syndrome (ARDS), ...

Researchers may have discovered a mechanical explanation for instability observed in the lungs in cases of acute respiratory distress syndrome (ARDS), particularly in the aftermath of respiratory ...

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the ...

Waiting for Response on Pre-IND Submission for TSC in COVID-19 ARDS On April 27, 2020, Diffusion Pharmaceuticals, Inc. DFFN announced the company's Pre-IND submission to the U.S. FDA for the use of ...